Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's

Read the full 200 word article

How to gain access

Continue reading with a
two-week free trial.